NCT04669821已完成2 期
A Multi-Center, Randomized, Open-Label, Propofol-Controlled Exploratory Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 Injectable Emulsion in ICU Patients Undergoing Long-Term Mechanical Ventilation
Haisco Pharmaceutical Group Co., Ltd.1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2021年3月9日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Mean duration of qualified sedation
研究概览
简要总结
This is a multi-center, randomized, open-label, propofol-controlled exploratory clinical study. In this study, 20 ICU patients undergoing mechanical ventilation are expected to be enrolled and will be randomly assigned to the HSK3486 group and the propofol group in a 1:1 ratio. This study is not blinded as it is open-label.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who require tracheal intubation for mechanical ventilation, with expected sedation duration of longer than 96 h;
- •Patients requiring a target RASS score of -1 to -2 for sedation;
- •Aged ≥ 18 and < 80 years old, with no gender requirement;
- •BMI ≥ 18 kg/m2 and ≤ 30 kg/m2;
- •The patients or their family members fully understand the objectives and significance of this study, and voluntarily participate in this clinical study and sign the informed consent form.
排除标准
- •Patients known to be allergic to eggs, soy products, opioids and their antidotes, and Propofol; patient having contraindications to Propofol, opioids and their antidotes;
- •Patients who have received propofol for more than 3 days in the ICU or in the general ward before being transferred to the ICU before signing informed consent form;
- •Patients having the following medical history or evidence of any of the following at screening, which may increase sedation/anesthesia risk:
- •Cardiovascular system: New York Heart Association (NYHA) Class III and IV heart failure, Adams-stokes syndrome; acute coronary syndrome (ACS) that occurs within 6 months before screening; bradycardia requiring medication and/or heart rate ≤ 50 beats/min; a history of severe arrhythmia such as II-III degree atrioventricular block (excluding patients using pacemakers); acute and chronic myocarditis;
- •Patients with hyperlipidemia: Defined as patients with TC ≥ 5.2 mmol/L or LDL-C ≥ 3.4 mmol/L at screening, or patients with severely increased blood pressure or blood glucose despite their blood lipid levels meeting the requirements, rendering the patients huge risk of cardiovascular diseases per the investigator's judgment; patients with acute pancreatitis;
- •Patients with mental diseases (e.g., schizophrenia, depression) and cognitive dysfunction; grand mal epilepsy and convulsion; head injury, intracranial hypertension, cerebral aneurysm; Glasgow Coma Score (GCS) ≤ 12; SOFA Score > 9; past history of psychotropic and narcotic drug abuse; history of alcohol abuse within 3 months before screening; long-term use of psychotropic drugs;
- •Patients with high paraplegia and general paralysis; patients with unstable hemodynamics;
- •Severe hepatic and renal insufficiency (liver function: refer to child-pugh grade C; renal function: glomerular filtration rate eGFR ≤ 30 mL/(min•1.73 m2) [eGFR is calculated using the Modification of Diet in Renal Disease (MDRD) equation: eGFR = 175 × serum creatinine (SCr)-1.234 × age-0.179 × 0.79 (females)]; patients undergoing dialysis;
- •Patients with an expected survival of less than 1 week;
- •Other situations unsuitable for enrollment per the investigator's consideration.
- •Pregnant or breastfeeding females: women or men of child-bearing potential who are unwilling to use contraception during the trial; subjects who are planning pregnancy within 1 month after the trial starts (including male subjects);
- •Have participated in any other clinical trials within 1 month prior to screening;
- •Other conditions that patients are judged by the investigator to be unsuitable for participating in the study.
研究组 & 干预措施
HSK3486
Experimental
干预措施: HSK3486 (Drug)
Propofol
Active Comparator
干预措施: Propofol (Drug)
结局指标
主要结局
Mean duration of qualified sedation
时间窗: Within 96hours of administration
the mean duration of RASS being in the range of -1 to -2 per hour during the study medication provided that no remedial medication is used
次要结局
- Time to recovery(Within 24 hours after administration)
- Time to extubation(Within 24 hours after administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating the Efficacy and Safety of HSK3486 for SedationSedationNCT04147416Sichuan Haisco Pharmaceutical Group Co., Ltd39
已完成
2 期
A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery PatientsInduction and Maintenance of General AnesthesiaNCT04048811Sichuan Haisco Pharmaceutical Group Co., Ltd46
招募中
不适用
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DESCoronary Artery DiseaseNCT05770674Kiyuk Chang2,186
尚未招募
4 期
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisBreast Cancer Stage IVNCT05860907Fudan University384
已完成
2 期
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06249854Korea Institute of Oriental Medicine26